Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2016 Earnings Results

Alnylam Pharmaceuticals Beats on EPS, Stock Down 0.5%

Alnylam Pharmaceuticals reported a narrower loss than expected, which is a positive sign for investors. However, the stock reacted negatively, declining by 0.5%. This could indicate that investors were looking for more concrete guidance or revenue figures, which were not provided.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	-$1.05	N/A	+16.53%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management expressed a cautious optimism about their ongoing projects. They acknowledged the challenges but remain focused on future developments.

Management highlighted progress in their pipeline despite the loss.

They emphasized commitment to long-term growth and innovation.

Alnylam Pharmaceuticals Beats on EPS, Stock Down 0.5%

Key numbers

Management commentary

Alnylam Pharmaceuticals, Inc.

More earnings this week

Alnylam Pharmaceuticals Beats on EPS, Stock Down 0.5%

Key numbers

Management commentary